Primary Job Title Co-Founder Primary Organization Tmunity Therapeutics
Location Philadelphia, Pennsylvania, United States Regions Greater Philadelphia Area, Great Lakes, Northeastern US Gender Male
LinkedIn View on LinkedIn
Yangbing Zhao is currently the Director of the TCEL at the Abramson Cancer Center and Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine. He is a graduate of the Third Medical University in Chongqing, China, where he received his PhD and MD. He was a
postdoctoral student and visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, from 1996 – 2000 where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation.
For the next two years he was a research associate at Duke University Medical Center in Durham, North Carolina, where he worked on RNA transfected dendritic cell vaccines against tumors. Next, he was a research fellow at the Surgery Branch of the National Cancer Institute at the U.S. National Institutes of Health from 2003 – 2008 where he developed NY-ESO-1 TCR and Her2/Neu CAR transduced T cells into clinical trials.
From there, he joined The Translational Research Program under Carl June where he became the director of the TCEL. He is also currently a member of the International Society for the Biological Therapy of Cancer (ISBTC).
